Symbols / HCWB
HCWB Chart
About
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.85M |
| Enterprise Value | 7.25M | Income | -22.21M | Sales | 422.03K |
| Book/sh | -0.80 | Cash/sh | 0.41 | Dividend Yield | — |
| Payout | 0.00% | Employees | 36 | IPO | — |
| P/E | — | Forward P/E | -1.03 | PEG | — |
| P/S | 4.39 | P/B | -0.70 | P/C | — |
| EV/EBITDA | -0.62 | EV/Sales | 17.17 | Quick Ratio | 0.04 |
| Current Ratio | 0.06 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -13.81 | EPS next Y | -0.55 | EPS Growth | — |
| Revenue Growth | -96.30% | Earnings | 2025-11-14 16:00 | ROA | -31.66% |
| ROE | — | ROIC | — | Gross Margin | 20.00% |
| Oper. Margin | -210.95% | Profit Margin | 0.00% | Shs Outstand | 3.28M |
| Shs Float | 2.47M | Short Float | 1.91% | Short Ratio | 0.65 |
| Short Interest | — | 52W High | 17.80 | 52W Low | 0.53 |
| Beta | 0.72 | Avg Volume | 78.17K | Volume | 17.13K |
| Target Price | $8.00 | Recom | None | Prev Close | $0.57 |
| Price | $0.56 | Change | -0.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$0.53
Latest analyst target
3. DCF / Fair value
$-50.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.53
Low
$8.00
High
$8.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-29 | main | Maxim Group | Buy → Buy | $35 |
| 2023-04-19 | reit | EF Hutton | — → Buy | $9 |
| 2023-03-30 | reit | EF Hutton | — → Buy | $9 |
| 2023-03-23 | reit | EF Hutton | — → Buy | $9 |
| 2022-11-08 | init | JonesTrading | — → Buy | $8 |
| 2022-03-24 | init | Maxim Group | — → Buy | $4 |
| 2021-11-19 | init | EF Hutton | — → Buy | $10 |
- HCW Biologics lines up $1.5M, cuts warrant price to $0.6055 - Stock Titan ue, 17 Feb 2026 08
- HCW Biologics Inc. Stock (HCWB) Opinions on Next-Gen Immunotherapy Platform Unveiling - Quiver Quantitative Mon, 25 Aug 2025 07
- Insiders' US$3.05m Investments In Red Following HCW Biologics' US$1.1m Dip In Market Value - simplywall.st hu, 20 Nov 2025 08
- HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewswire Wed, 18 Feb 2026 02
- HCW Biologics Completes Follow-On Offering to Fund Pipeline - TipRanks hu, 19 Feb 2026 22
- Insiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9m - Yahoo Finance Wed, 02 Jul 2025 07
- Inside HCW Biologics’ $7M deal to test a new cancer drug in China - Stock Titan Fri, 13 Feb 2026 08
- HCW Biologics Announces Follow-On Offering Pricing - Intellectia AI Wed, 18 Feb 2026 03
- HCW Biologics Restructures Obligations to Regain Nasdaq Compliance - The Globe and Mail hu, 01 Jan 2026 08
- HCWB Stock Soars 82% on Breakthrough Cancer Therapy Results - Tokenist Fri, 12 Sep 2025 07
- HCW Biologics Inc.’s Financial Leap: What’s Next? - StocksToTrade Mon, 25 Aug 2025 07
- HCW Biologics Stock Scores Biggest Gain Since May As Cancer Drug Breakthrough Fuels Blockbuster Hopes - Stocktwits ue, 26 Aug 2025 07
- HCW Biologics enters $7 million licensing deal with China-based Trimmune - Investing.com Nigeria Fri, 13 Feb 2026 08
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 11
- Breakthrough Cancer Drug Outperforms $40B Keytruda: HCW Biologics' New Immunotherapy Shows Superior Results - Stock Titan Mon, 25 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 13423 | 100001 | — | Purchase at price 7.45 per share. | GARRETT SCOTT T | Director | — | 2025-05-16 00:00:00 | D |
| 1 | 1342 | 9998 | — | Purchase at price 7.45 per share. | WINER GARY M | Director | — | 2025-05-16 00:00:00 | D |
| 2 | 8054 | 60002 | — | Purchase at price 7.45 per share. | WONG HING C | Chief Executive Officer | — | 2025-05-16 00:00:00 | D |
| 3 | 5385 | 38503 | — | Purchase at price 7.15 per share. | GARRETT SCOTT T | Director | — | 2025-05-08 00:00:00 | D |
| 4 | 962 | 6878 | — | Purchase at price 7.15 per share. | GREENE RICK SCOTT | Director | — | 2025-05-08 00:00:00 | D |
| 5 | 2308 | 16502 | — | Purchase at price 7.15 per share. | WINER GARY M | Director | — | 2025-05-08 00:00:00 | D |
| 6 | 92500 | 661375 | — | Purchase at price 7.15 per share. | WONG HING C | Chief Executive Officer | — | 2025-05-08 00:00:00 | D |
| 7 | 8462 | 60503 | — | Purchase at price 7.15 per share. | BYAM REBECCA | Chief Financial Officer | — | 2025-05-08 00:00:00 | D |
| 8 | 962 | 6878 | — | Purchase at price 7.15 per share. | FLOWERS LEE | Officer | — | 2025-05-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -27.68M | -23.58M | -14.06M | -12.32M |
| TotalUnusualItems | -15.91M | -6.57M | ||
| TotalUnusualItemsExcludingGoodwill | -15.91M | -6.57M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.02M | -24.99M | -14.90M | -12.86M |
| ReconciledDepreciation | 1.18M | 1.14M | 717.85K | 543.60K |
| ReconciledCostOfRevenue | 700.55K | 1.41M | 3.76M | 0.00 |
| EBITDA | -27.68M | -23.58M | -14.06M | -12.32M |
| EBIT | -28.87M | -24.71M | -14.77M | -12.86M |
| NetInterestIncome | -1.16M | -283.04K | -126.66K | 0.00 |
| InterestExpense | 1.16M | 283.04K | 126.66K | 0.00 |
| InterestIncome | 505.37K | |||
| NormalizedIncome | -30.02M | -24.99M | -14.90M | -12.86M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.02M | -24.99M | -14.90M | -12.86M |
| TotalExpenses | 31.52M | 28.56M | 21.80M | 13.37M |
| RentExpenseSupplemental | 205.51K | 156.81K | 132.74K | 100.46K |
| TotalOperatingIncomeAsReported | -29.48M | -25.72M | -15.08M | -13.37M |
| DilutedAverageShares | 969.83K | 898.24K | 895.56K | 469.27K |
| BasicAverageShares | 969.83K | 898.24K | 895.56K | 469.27K |
| DilutedEPS | -30.80 | -28.00 | -16.80 | -27.60 |
| BasicEPS | -30.80 | -28.00 | -16.80 | -27.60 |
| DilutedNIAvailtoComStockholders | -30.02M | -24.99M | -14.90M | -12.86M |
| NetIncomeCommonStockholders | -30.02M | -24.99M | -14.90M | -12.86M |
| NetIncome | -30.02M | -24.99M | -14.90M | -12.86M |
| NetIncomeIncludingNoncontrollingInterests | -30.02M | -24.99M | -14.90M | -12.86M |
| NetIncomeContinuousOperations | -30.02M | -24.99M | -14.90M | -12.86M |
| PretaxIncome | -30.02M | -24.99M | -14.90M | -12.86M |
| OtherIncomeExpense | 86.99K | 1.01M | 304.74K | 505.37K |
| OtherNonOperatingIncomeExpenses | 86.99K | 1.01M | 304.74K | 505.37K |
| SpecialIncomeCharges | -15.91M | -6.57M | ||
| OtherSpecialCharges | 15.91M | 6.57M | ||
| NetNonOperatingInterestIncomeExpense | -1.16M | -283.04K | -126.66K | 0.00 |
| InterestExpenseNonOperating | 1.16M | 283.04K | 126.66K | 0.00 |
| InterestIncomeNonOperating | 505.37K | |||
| OperatingIncome | -28.95M | -25.72M | -15.08M | -13.37M |
| OperatingExpense | 29.91M | 26.28M | 17.67M | 13.37M |
| ProvisionForDoubtfulAccounts | 1.30M | 5.25M | 0.00 | |
| DepreciationAmortizationDepletionIncomeStatement | 277.55K | 266.76K | 338.46K | 218.47K |
| DepreciationAndAmortizationInIncomeStatement | 277.55K | 266.76K | 338.46K | 218.47K |
| DepreciationIncomeStatement | 277.55K | 266.76K | 338.46K | 218.47K |
| ResearchAndDevelopment | 6.39M | 7.68M | 9.34M | 8.17M |
| SellingGeneralAndAdministration | 21.95M | 13.08M | 7.99M | 4.98M |
| GeneralAndAdministrativeExpense | 21.95M | 13.08M | 7.99M | 4.98M |
| OtherGandA | 19.18M | 9.71M | 4.48M | 2.53M |
| RentAndLandingFees | 205.51K | 156.81K | 132.74K | 100.46K |
| SalariesAndWages | 2.56M | 3.22M | 3.38M | 2.34M |
| GrossProfit | 959.40K | 560.36K | 2.59M | 0.00 |
| CostOfRevenue | 1.61M | 2.28M | 4.14M | 0.00 |
| TotalRevenue | 2.57M | 2.84M | 6.72M | 0.00 |
| OperatingRevenue | 2.57M | 2.84M | 6.72M | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.11M | 900.63K | 896.91K | 894.21K |
| ShareIssued | 1.11M | 900.63K | 896.91K | 894.21K |
| NetDebt | 9.02M | 2.71M | ||
| TotalDebt | 13.69M | 6.30M | 6.41M | |
| TangibleBookValue | -6.77M | 13.46M | 37.43M | 51.19M |
| InvestedCapital | 6.92M | 19.77M | 43.84M | 51.19M |
| WorkingCapital | -23.93M | -2.34M | 31.11M | 38.16M |
| NetTangibleAssets | -6.77M | 13.46M | 37.43M | 51.19M |
| CommonStockEquity | -6.77M | 13.46M | 37.43M | 51.19M |
| TotalCapitalization | 607.69K | 19.77M | 43.84M | 51.19M |
| TotalEquityGrossMinorityInterest | -6.77M | 13.46M | 37.43M | 51.19M |
| StockholdersEquity | -6.77M | 13.46M | 37.43M | 51.19M |
| RetainedEarnings | -100.56M | -70.53M | -45.54M | -30.64M |
| AdditionalPaidInCapital | 93.78M | 83.99M | 82.96M | 81.83M |
| CapitalStock | 4.45K | 3.60K | 3.59K | 3.58K |
| CommonStock | 4.45K | 3.60K | 3.59K | 3.58K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 37.01M | 15.05M | 9.38M | 2.32M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.38M | 6.30M | 6.42M | 0.00 |
| OtherNonCurrentLiabilities | 14.28K | |||
| LongTermDebtAndCapitalLeaseObligation | 7.38M | 6.30M | 6.41M | |
| LongTermDebt | 7.38M | 6.30M | 6.41M | |
| CurrentLiabilities | 29.63M | 8.75M | 2.96M | 2.32M |
| CurrentDebtAndCapitalLeaseObligation | 6.31M | |||
| CurrentDebt | 6.31M | |||
| LineOfCredit | 6.31M | 0.00 | ||
| PayablesAndAccruedExpenses | 23.31M | 8.75M | 2.96M | 2.32M |
| CurrentAccruedExpenses | 981.94K | 2.58M | 1.73M | 2.10M |
| Payables | 22.33M | 6.17M | 1.23M | 223.66K |
| AccountsPayable | 22.33M | 6.17M | 1.23M | 223.66K |
| TotalAssets | 30.24M | 28.51M | 46.81M | 53.51M |
| TotalNonCurrentAssets | 24.54M | 22.11M | 12.74M | 13.03M |
| OtherNonCurrentAssets | 28.48K | 56.54K | 333.88K | 393.32K |
| InvestmentsAndAdvances | 1.60M | 1.60M | 1.60M | 11.52M |
| NetPPE | 22.91M | 20.45M | 10.80M | 1.12M |
| AccumulatedDepreciation | -3.68M | -3.03M | -2.24M | -1.65M |
| GrossPPE | 26.59M | 23.49M | 13.04M | 2.77M |
| Leases | 354.28K | 354.28K | 349.98K | 349.98K |
| ConstructionInProgress | 13.55M | 10.44M | 52.41K | 0.00 |
| OtherProperties | 3.91M | 3.91M | 3.88M | 1.95M |
| MachineryFurnitureEquipment | 517.41K | 517.41K | 501.45K | 467.41K |
| BuildingsAndImprovements | 6.11M | 6.11M | 6.11M | 0.00 |
| LandAndImprovements | 2.15M | 2.15M | 2.15M | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.70M | 6.40M | 34.07M | 40.48M |
| OtherCurrentAssets | 113.53K | 230.92K | 196.01K | 1.44M |
| PrepaidAssets | 328.18K | 1.04M | 1.39M | 2.20M |
| Receivables | 582.20K | 1.54M | 417.69K | 133.00K |
| AccountsReceivable | 582.20K | 1.54M | 417.69K | 133.00K |
| CashCashEquivalentsAndShortTermInvestments | 4.67M | 3.60M | 32.06M | 36.71M |
| OtherShortTermInvestments | 0.00 | 9.74M | 24.98M | |
| CashAndCashEquivalents | 4.67M | 3.60M | 22.33M | 11.73M |
| CashEquivalents | 3.75M | 1.63M | 19.46M | |
| CashFinancial | 926.25K | 1.97M | 2.87M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.49M | -28.72M | -20.66M | -11.02M |
| RepaymentOfDebt | -119.40K | -38.27K | 0.00 | |
| IssuanceOfDebt | 6.91M | 0.00 | 6.45M | 0.00 |
| IssuanceOfCapitalStock | 6.46M | 23.74K | 15.78K | 56.03M |
| CapitalExpenditure | -261.62K | -6.20M | -10.28M | -47.26K |
| InterestPaidSupplementalData | 569.77K | 283.04K | 126.66K | 0.00 |
| EndCashPosition | 4.67M | 3.60M | 22.33M | 11.73M |
| BeginningCashPosition | 3.60M | 22.33M | 11.73M | 8.46M |
| ChangesInCash | 1.08M | -18.73M | 10.60M | 3.27M |
| FinancingCashFlow | 15.57M | -14.53K | 6.27M | 49.27M |
| CashFlowFromContinuingFinancingActivities | 15.57M | -14.53K | 6.27M | 49.27M |
| NetOtherFinancingCharges | -638.04K | -190.55K | -6.76M | |
| ProceedsFromStockOptionExercised | 2.96M | 0.00 | ||
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 6.46M | 23.74K | 15.78K | 56.03M |
| CommonStockIssuance | 6.46M | 23.74K | 15.78K | 56.03M |
| NetIssuancePaymentsOfDebt | 6.79M | -38.27K | 6.45M | 0.00 |
| NetLongTermDebtIssuance | 6.79M | -38.27K | 6.45M | 0.00 |
| LongTermDebtPayments | -119.40K | -38.27K | 0.00 | |
| LongTermDebtIssuance | 6.91M | 0.00 | 6.45M | 0.00 |
| InvestingCashFlow | -261.62K | 3.80M | 14.71M | -35.02M |
| CashFlowFromContinuingInvestingActivities | -261.62K | 3.80M | 14.71M | -35.02M |
| NetInvestmentPurchaseAndSale | 0.00 | 10.00M | 24.98M | -34.97M |
| SaleOfInvestment | 0.00 | 10.00M | 24.98M | 0.00 |
| PurchaseOfInvestment | 0.00 | -34.97M | ||
| NetPPEPurchaseAndSale | -261.62K | -6.20M | -10.28M | -47.26K |
| PurchaseOfPPE | -261.62K | -6.20M | -10.28M | -47.26K |
| OperatingCashFlow | -14.23M | -22.51M | -10.39M | -10.98M |
| CashFlowFromContinuingOperatingActivities | -14.23M | -22.51M | -10.39M | -10.98M |
| ChangeInWorkingCapital | 13.60M | -4.64M | 2.49M | 1.46M |
| ChangeInOtherCurrentLiabilities | -56.54K | -326.74K | -128.25K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 11.87M | 1.62M | 418.21K | 1.89M |
| ChangeInPayable | 11.87M | 1.62M | 418.21K | 1.89M |
| ChangeInAccountPayable | 11.87M | 1.62M | 418.21K | 1.89M |
| ChangeInPrepaidAssets | 831.62K | -4.82M | 2.48M | -2.80M |
| ChangeInReceivables | 953.56K | -1.12M | -284.69K | 2.37M |
| ChangesInAccountReceivables | 953.56K | -1.12M | -284.69K | 2.37M |
| OtherNonCashItems | -418.00 | -1.67K | 2.09K | 28.26K |
| StockBasedCompensation | 1.01M | 1.00M | 1.12M | 360.98K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -248.44K | 186.37K | 65.83K |
| ProvisionandWriteOffofAssets | 0.00 | 5.25M | 0.00 | |
| DepreciationAmortizationDepletion | 1.18M | 1.14M | 717.85K | 543.60K |
| DepreciationAndAmortization | 1.18M | 1.14M | 717.85K | 543.60K |
| OperatingGainsLosses | -15.62K | -567.31K | ||
| GainLossOnInvestmentSecurities | -15.62K | |||
| NetIncomeFromContinuingOperations | -30.02M | -24.99M | -14.90M | -12.86M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HCWB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|